Related Experiment Video
Updated: Dec 21, 2025
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
15.2K
Summary
Elevated interleukin-8 (IL8) levels in the blood indicate poor response to immune checkpoint inhibitors. Combining IL8 inhibitors with PD-1 drugs may improve patient outcomes.
Area of Science:
- Oncology
- Immunology
- Biomarkers
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
- Predicting patient response to ICIs remains a challenge.
- The role of specific cytokines in ICI response needs further elucidation.
Purpose of the Study:
- To investigate the prognostic value of interleukin-8 (IL8) in patients treated with ICIs.
- To explore the potential of targeting the IL8 pathway in combination with ICIs.
Main Methods:
- Analysis of blood IL8 levels in patients undergoing ICI therapy.
- Correlation of IL8 levels with treatment response and clinical outcomes.
- Review of existing literature and preclinical data.
Main Results:
- Two independent studies identified high blood IL8 levels as a negative prognostic indicator for ICI response.
- Elevated IL8 is associated with diminished therapeutic efficacy of PD-1 pathway inhibitors.
Conclusions:
- Interleukin-8 (IL8) is a potential predictive biomarker for ICI therapy.
- Targeting the IL8 axis in combination with PD-1 inhibitors presents a promising therapeutic strategy for enhancing anti-tumor immunity.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.9K
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.0K